NOCIL Limited share price
NSE: NOCIL · ISIN INE163A01018
Key numbers
- Market cap
- ₹ 3,147 Cr
- Current price
- ₹ 188.41
- 52-week high / low
- ₹ 211 / 125
- Stock P/E
- 47.8
- Book value
- ₹ 106.2
- Dividend yield
- 0.80%
- ROCE
- 4.4%
- ROE
- 3.1%
- Debt to equity
- 0.00
- Sales growth (3 yrs)
- -7.4%
- Profit growth (3 yrs)
- -28.0%
- 1-year return
- 4.1%
About NOCIL Limited
NOCIL Limited engages in the manufacture and sale of rubber chemicals for tire, automotive, rubber goods, and industrial sectors in India and internationally. It provides rubber chemicals, including pilflex, pilnox, pilcure, and pilgard, as well as anti-degradants/anti-oxidants accelerators. The company also offers technical services. NOCIL Limited was incorporated in 1961 and is headquartered in Mumbai, India.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 340 | 336 | 316 | 330 | 403 |
| Operating profit | 34 | 31 | 27 | 21 | 45 |
| Net profit | 21 | 17 | 9 | 17 | 28 |
| EPS (₹) | 1.25 | 1.03 | 0.55 | 1.02 | 1.66 |
Concall summary (2026-08-10)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- The net revenue from operations for Q1 FY27 stood at Rs 403 crores, registering a strong growth of 20% YoY from Rs 336 crores in Q1 FY26, and 22% QoQ from Rs 330 crores in Q4 FY26.
- As Anand stated, volumes recorded a healthy 9% YoY growth in Q1 FY27 compared with Q1 FY26, while we witnessed a moderate 3% sequential decline compared to Q4 FY26 due to temporary supply side constraints and other logistics issues.
Growth & demand
- 403 crores, reflecting an impressive 20% year -on-year growth driven by growing volumes and increase in selling prices on account of increase in raw material costs.
- The company delivered a healthy 9% volume growth compared to Q1 Financial Year ‘26, driven by sustained demand across key end markets.
Margins & costs
- We expect revenue for Financial Year ‘27 to be in the range of Rs 1,400 to Rs 1,600 crores, based on the current pricing environment, with EBITDA in the region of 10%.
- EBITDA margins for Q1 FY27 stood at 11.2%, expanding by 210 basis points YoY compared to Q1 FY26, and by 480 basis points QoQ compared to Q4 FY26.
Capex & expansion
- Coming back to NOCIL, trial production at our new TDQ plant in Dahej is coming along well with initiation of samples to customers.
- Our new Rs 130 crore investment in Dahej is also progressing well, and our teams have done a great job of keeping it on track in spite of the challenges and disruptions we have been witnessing on account of the war in the last few months.
Balance sheet & cash
- And it is a combination of volume, also product mix, also coming from the fact that better price realization in the domestic market for accelerators, and operating leverages that will come.
Peers in Specialty Chemicals
Data for information only, not investment advice. Prices end of day.